pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

161 catalysts · 39 phase 2 completion · 30 phase 1 completion · 22 phase 1 2 completion · 17 phase 2 initiation · 17 phase 1 initiation · 12 phase 1 2 initiation

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-20: 0 catalysts2026-07-21: 0 catalysts2026-07-22: 0 catalysts2026-07-23: 0 catalysts2026-07-24: 0 catalysts2026-07-25: 0 catalysts2026-07-26: 0 catalysts2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: epilepsy×TA: cardiology×TA: oncology×clear all
type
  • phase 2 completion39
  • phase 1 completion30
  • phase 1 2 completion22
  • phase 2 initiation17
  • phase 1 initiation17
  • phase 1 2 initiation12
phase 0 trial completion8
  • phase 3 completion4
  • phase 2 results3
  • phase 3 initiation3
  • therapy area
    • Oncology127
    • Infectious Disease38
    • Cardiology36
    • Immunology28
    • Dermatology26
    • Pulmonology18
    • Women's Health15
    • Ophthalmology14
    • Pain11

    Week of Apr 27, 2026

    50
    ›Apr 29, 2026phase 3 initiation88d agoIncyte Corp — retifanlimab (Phase III Trial Initiation)retifanlimab

    Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Hypopharyngeal Cancer, Laryngeal Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Recurrent Head And Neck Squamous Cell Carcinoma

    full page →retifanlimab →source: globaldata
    ›Apr 29, 2026phase 3 initiation88d agoInstitute of Hematology and Blood Diseases Hospital — venetoclax (Phase III Trial Initiation)venetoclax

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

    full page →venetoclax →source: globaldata
    ›Apr 29, 2026phase iv trial initiation88d agoNucleic Acids to the Rescue GmbH — undisclosed chemotherapy (Phase IV Trial Initiation)undisclosed chemotherapy

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →undisclosed chemotherapy →source: globaldata
    ›Apr 30, 2026constraining patent expiry europe87d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

    Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

    full page →telavancin hydrochloride →source: globaldata
    ›Apr 30, 2026fda advisory committee meeting87d agoAstraZeneca Plc — camizestrant (FDA Advisory Committee Meeting)camizestrant

    Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

    full page →camizestrant →source: globaldata
    ›Apr 30, 2026fda advisory committee meeting87d agoAstraZeneca Plc — capivasertib (FDA Advisory Committee Meeting)capivasertib

    Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer

    full page →capivasertib →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoSecond Affiliated Hospital of Anhui Medical University — yingtao shujie paste (Phase 0 Trial Completion)yingtao shujie paste

    Therapy area: Oncology, Women's Health. Indication: Breast Cancer, Breast Hyperplasia

    full page →yingtao shujie paste →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoCivil Aviation General Hospital — dexmedetomidine (Phase 0 Trial Completion)dexmedetomidine

    Therapy area: Cardiovascular, Respiratory. Indication: Ischemia Reperfusion Injury, Lung Disease

    full page →dexmedetomidine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoHefei First People’s Hospital — ergothioneine (Phase 0 Trial Completion)ergothioneine

    Therapy area: Cardiovascular. Indication: Atherosclerosis

    full page →ergothioneine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoKey Projects of Science and Technology Department of Sichuan Province — dantrolene (Phase 0 Trial Completion)dantrolene

    Therapy area: Cardiovascular. Indication: Ischemia, Myocardial Ischemia, Ventricular Arrhythmia

    full page →dantrolene →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoJiangsu Maoxing Technology Co Ltd — MT-026 (Phase 0 Trial Completion)MT-026

    Therapy area: Oncology. Indication: Glioma

    full page →MT-026 →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoFirst Affiliated Hospital of Anhui Medical University — esketamine (Phase 0 Trial Completion)esketamine

    Therapy area: Central Nervous System, Oncology. Indication: Post-Operative Pain, Thyroid Cancer

    full page →esketamine →source: globaldata
    ›Apr 30, 2026phase 0 trial completion87d agoInner Mongolia Aerospace Hospital — (bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12) (Phase 0 Trial Completion)(bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12)

    Therapy area: Cardiovascular, Gastrointestinal. Indication: Atherosclerosis, Irritable Bowel Syndrome

    full page →(bifidobacterium lactis V9 + lactobacillus paracasei LP007 + lactobacillus plantarum PP12) →source: globaldata
    ›Apr 30, 2026phase 0 trial initiation87d agoWashington University School of Medicine — asciminib hydrochloride (Phase 0 Trial Initiation)asciminib hydrochloride

    Therapy area: Oncology. Indication: Brain Tumor

    full page →asciminib hydrochloride →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoChugai Pharmaceutical Co Ltd — tocilizumab (Phase I Trial Completion)tocilizumab

    Therapy area: Oncology. Indication: B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma

    full page →tocilizumab →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoNational Cancer Institute Center for Cancer Research — Anti-CD19/CD20/CD22 CAR T-cells (Phase I Trial Completion)Anti-CD19/CD20/CD22 CAR T-cells

    Therapy area: Oncology. Indication: Acute Lymphoblastic Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), B-Cell Leukemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Lymphoma, Non-Hodgkin Lymphoma, Unspecified B-Cell Lymphomas

    full page →Anti-CD19/CD20/CD22 CAR T-cells →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoEOC Pharma Ltd — EOC-237 (Phase I Trial Completion)EOC-237

    Therapy area: Oncology. Indication: Solid Tumor

    full page →EOC-237 →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoJiangxi Jemincare Group Co Ltd — JMKX-003142 (Phase I Trial Completion)JMKX-003142

    Therapy area: Cardiovascular, Genetic Disorders. Indication: Edema, Polycystic Kidney Disease

    full page →JMKX-003142 →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoChangzhou Hengbang Pharmaceutical Co Ltd — risvutatug rezetecan (Phase I Trial Completion)risvutatug rezetecan

    Therapy area: Oncology. Indication: Small-Cell Lung Cancer

    full page →risvutatug rezetecan →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoOncoNano Medicine Inc — cemiplimab (Phase I Trial Completion)cemiplimab

    Therapy area: Oncology. Indication: Basal Cell Carcinoma (Basal Cell Epithelioma), Bladder Cancer, Carcinomas, Cervical Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Head And Neck Squamous Cell Carcinoma (HNSC), Lymphoma, Mantle Cell Lymphoma, Melanoma, Non-Hodgkin Lymphoma, Skin Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Uveal Melanoma

    full page →cemiplimab →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoJiangsu Postgraduate Research and Practice Innovation Program — acetaminophen (Phase I Trial Completion)acetaminophen ER

    Therapy area: Cardiovascular. Indication: Patent Ductus Arteriosus

    full page →acetaminophen ER →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoNational Cancer Institute US — tuvusertib (Phase I Trial Completion)tuvusertib

    Therapy area: Oncology. Indication: Adenocarcinoma, Endometrial Cancer, Ovarian Cancer

    full page →tuvusertib →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoPhrae Hospital — bupivacaine (Phase I Trial Completion)bupivacaine

    Therapy area: Cardiovascular, Central Nervous System, Gastrointestinal. Indication: Hypotension, Post Operative Nausea And Vomiting, Post-Operative Pain

    full page →bupivacaine →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoTakeda Pharmaceutical Co Ltd — Cabometyx (Phase I Trial Completion)cabozantinib s-malate

    Therapy area: Oncology. Indication: Solid Tumor

    full page →cabozantinib s-malate →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoCellenkos Inc — CK-0804 (Phase I Trial Completion)CK-0804

    Therapy area: Oncology. Indication: Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF)

    full page →CK-0804 →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoBeOne Medicines AG — BG-89894 (Phase I Trial Completion)BG-89894

    Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Bladder Cancer, Esophageal Cancer, Gastric Cancer, Liver Cancer, Malignant Mesothelioma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Solid Tumor

    full page →BG-89894 →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoAngel Pharmaceuticals Inc — soquelitinib (Phase I Trial Completion)soquelitinib

    Therapy area: Oncology. Indication: Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Cutaneous T-Cell Lymphoma, Natural Killer Cell Lymphomas, Peripheral T-Cell Lymphomas (PTCL), T-Cell Leukemia, T-Cell Lymphomas

    full page →soquelitinib →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoKyowa Kirin Co Ltd — brentuximab vedotin (Phase I Trial Completion)brentuximab vedotin

    Therapy area: Oncology. Indication: Cutaneous T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome

    full page →brentuximab vedotin →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoShanghai Institute of Biological Products Co Ltd — SIBPA-13 (Phase I Trial Completion)SIBPA-13

    Therapy area: Oncology. Indication: Breast Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Non-Small Cell Lung Cancer, Solid Tumor

    full page →SIBPA-13 →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoSun Yat-sen University Hospital Seven — stiripentol (Phase I Trial Completion)stiripentol

    Therapy area: Oncology. Indication: Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer

    full page →stiripentol →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoNational Cancer Institute US — emavusertib hydrochloride (Phase I Trial Completion)emavusertib hydrochloride

    Therapy area: Oncology. Indication: Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma

    full page →emavusertib hydrochloride →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoUniversity of Texas MD Anderson Cancer Center — bevacizumab (Phase I Trial Completion)bevacizumab

    Therapy area: Oncology. Indication: Advanced Malignancy, Metastatic Cancer, Solid Tumor

    full page →bevacizumab →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoSiteman Cancer Center — soficabtagene geleucel (Phase I Trial Completion)soficabtagene geleucel

    Therapy area: Oncology. Indication: Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Cutaneous T-Cell Lymphoma, Natural Killer Cell Lymphomas, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sezary Syndrome, T-Cell Leukemia, T-Cell Lymphomas, Transformed Mycosis Fungoides

    full page →soficabtagene geleucel →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoRevolution Medicines Inc — daraxonrasib (Phase I Trial Completion)daraxonrasib

    Therapy area: Oncology. Indication: Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor

    full page →daraxonrasib →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoBarts Charity — undisclosed Covid-19 vaccine (Phase I Trial Completion)undisclosed Covid-19 vaccine

    Therapy area: Cardiovascular. Indication: Cardiovascular Disease, Endothelial Dysfunction

    full page →undisclosed Covid-19 vaccine →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoOno Pharmaceutical Co Ltd — ONO-4578 (Phase I Trial Completion)ONO-4578

    Therapy area: Oncology. Indication: Breast Cancer, Hormone Sensitive Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Breast Cancer

    full page →ONO-4578 →source: globaldata
    ›Apr 30, 2026phase 1 completion87d agoDaiichi Sankyo Co Ltd — raludotatug deruxtecan (Phase I Trial Completion)raludotatug deruxtecan

    Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Ovarian Cancer, Renal Cell Carcinoma

    full page →raludotatug deruxtecan →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoEgyptian International Pharmaceuticals Industries Co SAE — enoxaparin sodium biosimilar (Phase I Trial Initiation)enoxaparin sodium biosimilar

    Therapy area: Cardiovascular. Indication: Acute Coronary Syndrome, Congestive Heart Failure (Heart Failure), Deep Vein Thrombosis (DVT), Myocardial Infarction, Pulmonary Embolism, Thromboembolic Disease, Thromboembolism, Thrombosis, Unstable Angina, Venous (Vein) Thrombosis, Venous Thromboembolism

    full page →enoxaparin sodium biosimilar →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoQilu Pharmaceutical Co Ltd — QLS-5212 (Phase I Trial Initiation)QLS-5212

    Therapy area: Oncology. Indication: Solid Tumor

    full page →QLS-5212 →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoFirst Affiliated Hospital of Bengbu Medical University — Loberamisal (Phase I Trial Initiation)Loberamisal

    Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke

    full page →Loberamisal →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoVanderbilt-Ingram Cancer Center — nivolumab (Phase I Trial Initiation)nivolumab

    Therapy area: Oncology. Indication: Head And Neck Cancer, Head And Neck Squamous Cell Carcinoma (HNSC), Oral Cavity (Mouth) Cancer, Squamous Cell Carcinoma

    full page →nivolumab →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoGan & Lee Pharmaceuticals Co Ltd — GLR-2037 (Phase I Trial Initiation)GLR-2037

    Therapy area: Oncology. Indication: Prostate Cancer

    full page →GLR-2037 →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoBio-Innova Co Ltd — dapagliflozin (Phase I Trial Initiation)DAPAGLIFLOZIN

    Therapy area: Cardiovascular, Genito Urinary System, Metabolic Disorders. Indication: Cardiovascular Risk Factors, Diabetic Nephropathy, Type 1 Diabetes (Juvenile Diabetes), Type 2 Diabetes

    full page →DAPAGLIFLOZIN →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoAvance Clinical Pty Ltd — ZE-740282 (Phase I Trial Initiation)ZE-740282

    Therapy area: Oncology. Indication: Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Myeloproliferative Disorders, Polycythemia Vera

    full page →ZE-740282 →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoByterna Therapeutics Ltd — BR-101 (Phase I Trial Initiation)BR-101

    Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma

    full page →BR-101 →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoBristol-Myers Squibb Co — navlimetostat (Phase I Trial Initiation)navlimetostat

    Therapy area: Oncology. Indication: Biliary Tumor, Bladder Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Malignant Mesothelioma, Malignant Pleural Mesothelioma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Glioblastoma Multiforme (GBM), Solid Tumor, Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

    full page →navlimetostat →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoShanghai Henlius Biotech Inc — HLX-3901 (Phase I Trial Initiation)HLX-3901

    Therapy area: Oncology. Indication: Neuroendocrine Carcinoma, Small-Cell Lung Cancer

    full page →HLX-3901 →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoCentre Hospitalier Universitaire de Nice — Leucogenase (Phase I Trial Initiation)Leucogenase

    Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

    full page →Leucogenase →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoKexing Biopharm Co Ltd — GB-18 (Phase I Trial Initiation)GB-18

    Therapy area: Musculoskeletal Disorders, Oncology. Indication: Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cachexia, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Solid Tumor, Unspecified Cancer

    full page →GB-18 →source: globaldata
    ›Apr 30, 2026phase 1 initiation87d agoBeOne Medicines AG — BGC-0979 (Phase I Trial Initiation)BGC-0979

    Therapy area: Oncology. Indication: Solid Tumor

    full page →BGC-0979 →source: globaldata
    ← prev
    page 2 of 4
    next →
    $INCY117.67+0.84%
    $CPIX6.6100-5.37%
    $AZN169.26+0.59%
    $TAK17.24+2.50%
    $AZN169.26+0.59%
    $RVMD189.23+0.25%
    $ONC325.90-0.27%
    $ONC325.90-0.27%